Latest Health News

AMP Limited has announced a quarterly distribution of AUD 1.9069 per AMP Capital Notes 2 security, payable in September 2025, reflecting a total annualised yield of 7.57%.

TALi Digital has acquired the You Can Do It! Education program, integrating social-emotional learning into its digital health platform, supported by a $1.5 million equity raise to fund growth and technology reintegration.

Monash IVF Group has affirmed its compliance with ASX continuous disclosure rules following a clinical incident involving an embryo transfer error at its Clayton laboratory. The company clarified the materiality and timing of its disclosures in response to ASX inquiries.

HeraMED has partnered with RMIT University and the Digital Health CRC to develop AI-driven maternity care models focused on culturally diverse populations, aiming to improve pre-term delivery risk prediction and personalised care.

Unith Limited reports a remarkable 1100% increase in users on its Digital Humans platform over the past year, driven by organic growth and strategic global partnerships. The company is poised to accelerate growth with upcoming marketing campaigns and high-profile industry events.

Artrya Limited has submitted a pivotal FDA 510(k) application for its AI-powered Salix® Coronary Plaque module, aiming for clearance in Q3 2025 and a lucrative US commercial launch.

EVE Health Group’s subsidiary Nextract has inked a pivotal two-year agreement with TeleDocs Clinic, enabling nationwide online prescribing of its upcoming erectile dysfunction and dysmenorrhea products ahead of regulatory approval.

WCM Global Growth Limited has renewed its on-market share buy-back program for 12 months, signaling ongoing confidence in its capital management strategy amid evolving market conditions.

Thrive Tribe Technologies has announced a proposed 20, 1 share consolidation aimed at streamlining its capital structure, pending shareholder approval at the upcoming Extraordinary General Meeting.

Control Bionics is on track for its strongest financial year yet, driven by robust US and Australian sales and promising global trials of its NeuroStrip® device.

BetMakers Technology Group has successfully raised $11.5 million through a share placement aimed at repaying debt and funding strategic growth initiatives, including a potential acquisition in Nevada.

Island Pharmaceuticals has reported encouraging Phase 2a/b trial results for ISLA-101, demonstrating meaningful reductions in dengue viral load and symptoms in humans. The findings support further clinical development of this antiviral candidate.